Reviews Letairis


No reviews yet.

Letairis Drug Description
LETAIRIS
(ambrisentan) Tablets for Oral Use

WARNING
POTENTIAL LIVER INJURY
LETAIRIS (ambrisentan) cause elevation of liver
aminotransferases (ALT and AST) to at least 3 times the upper limit of normal
(ULN). LETAIRIS treatment was associated with aminotransferase elevations > 3
x ULN in 0.8% of patients in 12-week trials and 2.8% of patients including
long-term open-label trials out to one year. One case of aminotransferase
elevations > 3 x ULN has been accompanied by bilirubin elevations > 2 x
ULN. Because these changes are a marker for potentially serious liver injury,
serum aminotransferase levels (and bilirubin if aminotransferase levels are
elevated) must be measured prior to initiation of treatment and then monthly.
In the post-marketing period with another endothelin
receptor antagonist (ERA), bosentan, rare cases of unexplained hepatic
cirrhosis were reported after prolonged ( > 12 months) therapy. In at least
one case with bosentan, a late presentation (after > 20 months of treatment)
included pronounced elevations in aminotransferases and bilirubin levels
accompanied by non-specific symptoms, all of which resolved slowly over time
after discontinuation of the suspect drug. This case reinforces the importance
of strict adherence to the monthly monitoring schedule for the duration of
treatment.
Elevations in aminotransferases require close attention.
LETAIRIS should generally be avoided in patients with elevated
aminotransferases ( > 3 x ULN) at baseline because monitoring liver injury may
be more difficult. If liver aminotransferase elevations are accompanied by
clinical symptoms of liver injury (such as nausea, vomiting, fever, abdominal
pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin > 2
x ULN, treatment should be stopped. There is no experience with the re-introduction
of LETAIRIS in these circumstances.
CONTRAINDICATION: PREGNANCY
LETAIRIS is very likely to produce serious birth defects if used by pregnant
women, as this effect has been seen consistently when it is administered to
animals [see CONTRAINDICATIONS]. Pregnancy must
therefore be excluded before the initiation of treatment with LETAIRIS and
prevented during treatment and for one month after stopping treatment by the
use of two acceptable methods of contraception unless the patient has had
a tubal sterilization or chooses to use a Copper T 380A IUD or LNg 20 IUS,
in which case no additional contraception is needed. Obtain monthly pregnancy
tests.
Because of the risks of liver injury and birth defects, LETAIRIS is available
only through a special restricted distribution program called the LETAIRIS
Education and Access Program (LEAP), by calling 1-866-664-LEAP (5327). Only
prescribers and pharmacies registered with LEAP may prescribe and distribute
LETAIRIS. In addition, LETAIRIS may be dispensed only to patients who are
enrolled in and meet all conditions of LEAP [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION



What are the possible side effects of ambrisentan (Letairis)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling short of breath;
fast or pounding heartbeats;
swelling of the feet, ankles, or legs;
nausea, stomach pain, loss of appetite, low fever, itching;
dark urine, clay-colored stools; or
jaundice...
Read All Potential Side Effects for Letairis »




LETAIRIS is the brand name for ambrisentan, an endothelin
receptor antagonist that is selective for the endothelin type-A (ETA) receptor.
The chemical name of ambrisentan is
(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic
acid. It has a molecular formula of C22H22N2O4
and a molecular weight of 378.42. It contains a single chiral center determined
to be the (S) configuration and has the following structural formula:
Figure 1: Ambrisentan Structural Formula








Ambrisentan is a white to off-white, crystalline solid. It
is a carboxylic acid with a pKa of 4.0. Ambrisentan is practically insoluble in
water and in aqueous solutions at low pH. Solubility increases in aqueous
solutions at higher pH. In the solid state ambrisentan is very stable, is not
hygroscopic, and is not light sensitive.
LETAIRIS is available as 5 mg and 10 mg film-coated tablets
for once-daily oral administration. The tablets include the following inactive
ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate and
microcrystalline cellulose. The tablets are film-coated with a coating material
containing FD&C Red #40 aluminum lake, lecithin, polyethylene glycol,
polyvinyl alcohol, talc, and titanium dioxide. Each square, pale pink LETAIRIS
tablet contains 5 mg of ambrisentan. Each oval, deep pink LETAIRIS tablet
contains 10 mg of ambrisentan. LETAIRIS tablets are unscored.
Last reviewed on RxList: 7/16/2009




Letairis Drug Description
LETAIRIS
(ambrisentan) Tablets for Oral Use

WARNING
POTENTIAL LIVER INJURY
LETAIRIS (ambrisentan) cause elevation of liver
aminotransferases (ALT and AST) to at least 3 times the upper limit of normal
(ULN). LETAIRIS treatment was associated with aminotransferase elevations > 3
x ULN in 0.8% of patients in 12-week trials and 2.8% of patients including
long-term open-label trials out to one year. One case of aminotransferase
elevations > 3 x ULN has been accompanied by bilirubin elevations > 2 x
ULN. Because these changes are a marker for potentially serious liver injury,
serum aminotransferase levels (and bilirubin if aminotransferase levels are
elevated) must be measured prior to initiation of treatment and then monthly.
In the post-marketing period with another endothelin
receptor antagonist (ERA), bosentan, rare cases of unexplained hepatic
cirrhosis were reported after prolonged ( > 12 months) therapy. In at least
one case with bosentan, a late presentation (after > 20 months of treatment)
included pronounced elevations in aminotransferases and bilirubin levels
accompanied by non-specific symptoms, all of which resolved slowly over time
after discontinuation of the suspect drug. This case reinforces the importance
of strict adherence to the monthly monitoring schedule for the duration of
treatment.
Elevations in aminotransferases require close attention.
LETAIRIS should generally be avoided in patients with elevated
aminotransferases ( > 3 x ULN) at baseline because monitoring liver injury may
be more difficult. If liver aminotransferase elevations are accompanied by
clinical symptoms of liver injury (such as nausea, vomiting, fever, abdominal
pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin > 2
x ULN, treatment should be stopped. There is no experience with the re-introduction
of LETAIRIS in these circumstances.
CONTRAINDICATION: PREGNANCY
LETAIRIS is very likely to produce serious birth defects if used by pregnant
women, as this effect has been seen consistently when it is administered to
animals [see CONTRAINDICATIONS]. Pregnancy must
therefore be excluded before the initiation of treatment with LETAIRIS and
prevented during treatment and for one month after stopping treatment by the
use of two acceptable methods of contraception unless the patient has had
a tubal sterilization or chooses to use a Copper T 380A IUD or LNg 20 IUS,
in which case no additional contraception is needed. Obtain monthly pregnancy
tests.
Because of the risks of liver injury and birth defects, LETAIRIS is available
only through a special restricted distribution program called the LETAIRIS
Education and Access Program (LEAP), by calling 1-866-664-LEAP (5327). Only
prescribers and pharmacies registered with LEAP may prescribe and distribute
LETAIRIS. In addition, LETAIRIS may be dispensed only to patients who are
enrolled in and meet all conditions of LEAP [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION



What are the possible side effects of ambrisentan (Letairis)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling short of breath;
fast or pounding heartbeats;
swelling of the feet, ankles, or legs;
nausea, stomach pain, loss of appetite, low fever, itching;
dark urine, clay-colored stools; or
jaundice...
Read All Potential Side Effects for Letairis »




LETAIRIS is the brand name for ambrisentan, an endothelin
receptor antagonist that is selective for the endothelin type-A (ETA) receptor.
The chemical name of ambrisentan is
(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic
acid. It has a molecular formula of C22H22N2O4
and a molecular weight of 378.42. It contains a single chiral center determined
to be the (S) configuration and has the following structural formula:
Figure 1: Ambrisentan Structural Formula








Ambrisentan is a white to off-white, crystalline solid. It
is a carboxylic acid with a pKa of 4.0. Ambrisentan is practically insoluble in
water and in aqueous solutions at low pH. Solubility increases in aqueous
solutions at higher pH. In the solid state ambrisentan is very stable, is not
hygroscopic, and is not light sensitive.
LETAIRIS is available as 5 mg and 10 mg film-coated tablets
for once-daily oral administration. The tablets include the following inactive
ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate and
microcrystalline cellulose. The tablets are film-coated with a coating material
containing FD&C Red #40 aluminum lake, lecithin, polyethylene glycol,
polyvinyl alcohol, talc, and titanium dioxide. Each square, pale pink LETAIRIS
tablet contains 5 mg of ambrisentan. Each oval, deep pink LETAIRIS tablet
contains 10 mg of ambrisentan. LETAIRIS tablets are unscored.
Last reviewed on RxList: 7/16/2009




Letairis Drug Description
LETAIRIS
(ambrisentan) Tablets for Oral Use

WARNING
POTENTIAL LIVER INJURY
LETAIRIS (ambrisentan) cause elevation of liver
aminotransferases (ALT and AST) to at least 3 times the upper limit of normal
(ULN). LETAIRIS treatment was associated with aminotransferase elevations > 3
x ULN in 0.8% of patients in 12-week trials and 2.8% of patients including
long-term open-label trials out to one year. One case of aminotransferase
elevations > 3 x ULN has been accompanied by bilirubin elevations > 2 x
ULN. Because these changes are a marker for potentially serious liver injury,
serum aminotransferase levels (and bilirubin if aminotransferase levels are
elevated) must be measured prior to initiation of treatment and then monthly.
In the post-marketing period with another endothelin
receptor antagonist (ERA), bosentan, rare cases of unexplained hepatic
cirrhosis were reported after prolonged ( > 12 months) therapy. In at least
one case with bosentan, a late presentation (after > 20 months of treatment)
included pronounced elevations in aminotransferases and bilirubin levels
accompanied by non-specific symptoms, all of which resolved slowly over time
after discontinuation of the suspect drug. This case reinforces the importance
of strict adherence to the monthly monitoring schedule for the duration of
treatment.
Elevations in aminotransferases require close attention.
LETAIRIS should generally be avoided in patients with elevated
aminotransferases ( > 3 x ULN) at baseline because monitoring liver injury may
be more difficult. If liver aminotransferase elevations are accompanied by
clinical symptoms of liver injury (such as nausea, vomiting, fever, abdominal
pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin > 2
x ULN, treatment should be stopped. There is no experience with the re-introduction
of LETAIRIS in these circumstances.
CONTRAINDICATION: PREGNANCY
LETAIRIS is very likely to produce serious birth defects if used by pregnant
women, as this effect has been seen consistently when it is administered to
animals [see CONTRAINDICATIONS]. Pregnancy must
therefore be excluded before the initiation of treatment with LETAIRIS and
prevented during treatment and for one month after stopping treatment by the
use of two acceptable methods of contraception unless the patient has had
a tubal sterilization or chooses to use a Copper T 380A IUD or LNg 20 IUS,
in which case no additional contraception is needed. Obtain monthly pregnancy
tests.
Because of the risks of liver injury and birth defects, LETAIRIS is available
only through a special restricted distribution program called the LETAIRIS
Education and Access Program (LEAP), by calling 1-866-664-LEAP (5327). Only
prescribers and pharmacies registered with LEAP may prescribe and distribute
LETAIRIS. In addition, LETAIRIS may be dispensed only to patients who are
enrolled in and meet all conditions of LEAP [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION



What are the possible side effects of ambrisentan (Letairis)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling short of breath;
fast or pounding heartbeats;
swelling of the feet, ankles, or legs;
nausea, stomach pain, loss of appetite, low fever, itching;
dark urine, clay-colored stools; or
jaundice...
Read All Potential Side Effects for Letairis »




LETAIRIS is the brand name for ambrisentan, an endothelin
receptor antagonist that is selective for the endothelin type-A (ETA) receptor.
The chemical name of ambrisentan is
(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic
acid. It has a molecular formula of C22H22N2O4
and a molecular weight of 378.42. It contains a single chiral center determined
to be the (S) configuration and has the following structural formula:
Figure 1: Ambrisentan Structural Formula








Ambrisentan is a white to off-white, crystalline solid. It
is a carboxylic acid with a pKa of 4.0. Ambrisentan is practically insoluble in
water and in aqueous solutions at low pH. Solubility increases in aqueous
solutions at higher pH. In the solid state ambrisentan is very stable, is not
hygroscopic, and is not light sensitive.
LETAIRIS is available as 5 mg and 10 mg film-coated tablets
for once-daily oral administration. The tablets include the following inactive
ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate and
microcrystalline cellulose. The tablets are film-coated with a coating material
containing FD&C Red #40 aluminum lake, lecithin, polyethylene glycol,
polyvinyl alcohol, talc, and titanium dioxide. Each square, pale pink LETAIRIS
tablet contains 5 mg of ambrisentan. Each oval, deep pink LETAIRIS tablet
contains 10 mg of ambrisentan. LETAIRIS tablets are unscored.
Last reviewed on RxList: 7/16/2009




Letairis Drug Description
LETAIRIS
(ambrisentan) Tablets for Oral Use

WARNING
POTENTIAL LIVER INJURY
LETAIRIS (ambrisentan) cause elevation of liver
aminotransferases (ALT and AST) to at least 3 times the upper limit of normal
(ULN). LETAIRIS treatment was associated with aminotransferase elevations > 3
x ULN in 0.8% of patients in 12-week trials and 2.8% of patients including
long-term open-label trials out to one year. One case of aminotransferase
elevations > 3 x ULN has been accompanied by bilirubin elevations > 2 x
ULN. Because these changes are a marker for potentially serious liver injury,
serum aminotransferase levels (and bilirubin if aminotransferase levels are
elevated) must be measured prior to initiation of treatment and then monthly.
In the post-marketing period with another endothelin
receptor antagonist (ERA), bosentan, rare cases of unexplained hepatic
cirrhosis were reported after prolonged ( > 12 months) therapy. In at least
one case with bosentan, a late presentation (after > 20 months of treatment)
included pronounced elevations in aminotransferases and bilirubin levels
accompanied by non-specific symptoms, all of which resolved slowly over time
after discontinuation of the suspect drug. This case reinforces the importance
of strict adherence to the monthly monitoring schedule for the duration of
treatment.
Elevations in aminotransferases require close attention.
LETAIRIS should generally be avoided in patients with elevated
aminotransferases ( > 3 x ULN) at baseline because monitoring liver injury may
be more difficult. If liver aminotransferase elevations are accompanied by
clinical symptoms of liver injury (such as nausea, vomiting, fever, abdominal
pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin > 2
x ULN, treatment should be stopped. There is no experience with the re-introduction
of LETAIRIS in these circumstances.
CONTRAINDICATION: PREGNANCY
LETAIRIS is very likely to produce serious birth defects if used by pregnant
women, as this effect has been seen consistently when it is administered to
animals [see CONTRAINDICATIONS]. Pregnancy must
therefore be excluded before the initiation of treatment with LETAIRIS and
prevented during treatment and for one month after stopping treatment by the
use of two acceptable methods of contraception unless the patient has had
a tubal sterilization or chooses to use a Copper T 380A IUD or LNg 20 IUS,
in which case no additional contraception is needed. Obtain monthly pregnancy
tests.
Because of the risks of liver injury and birth defects, LETAIRIS is available
only through a special restricted distribution program called the LETAIRIS
Education and Access Program (LEAP), by calling 1-866-664-LEAP (5327). Only
prescribers and pharmacies registered with LEAP may prescribe and distribute
LETAIRIS. In addition, LETAIRIS may be dispensed only to patients who are
enrolled in and meet all conditions of LEAP [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION



What are the possible side effects of ambrisentan (Letairis)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling short of breath;
fast or pounding heartbeats;
swelling of the feet, ankles, or legs;
nausea, stomach pain, loss of appetite, low fever, itching;
dark urine, clay-colored stools; or
jaundice...
Read All Potential Side Effects for Letairis »




LETAIRIS is the brand name for ambrisentan, an endothelin
receptor antagonist that is selective for the endothelin type-A (ETA) receptor.
The chemical name of ambrisentan is
(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic
acid. It has a molecular formula of C22H22N2O4
and a molecular weight of 378.42. It contains a single chiral center determined
to be the (S) configuration and has the following structural formula:
Figure 1: Ambrisentan Structural Formula








Ambrisentan is a white to off-white, crystalline solid. It
is a carboxylic acid with a pKa of 4.0. Ambrisentan is practically insoluble in
water and in aqueous solutions at low pH. Solubility increases in aqueous
solutions at higher pH. In the solid state ambrisentan is very stable, is not
hygroscopic, and is not light sensitive.
LETAIRIS is available as 5 mg and 10 mg film-coated tablets
for once-daily oral administration. The tablets include the following inactive
ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate and
microcrystalline cellulose. The tablets are film-coated with a coating material
containing FD&C Red #40 aluminum lake, lecithin, polyethylene glycol,
polyvinyl alcohol, talc, and titanium dioxide. Each square, pale pink LETAIRIS
tablet contains 5 mg of ambrisentan. Each oval, deep pink LETAIRIS tablet
contains 10 mg of ambrisentan. LETAIRIS tablets are unscored.
Last reviewed on RxList: 7/16/2009




Letairis Drug Description
LETAIRIS
(ambrisentan) Tablets for Oral Use

WARNING
POTENTIAL LIVER INJURY
LETAIRIS (ambrisentan) cause elevation of liver
aminotransferases (ALT and AST) to at least 3 times the upper limit of normal
(ULN). LETAIRIS treatment was associated with aminotransferase elevations > 3
x ULN in 0.8% of patients in 12-week trials and 2.8% of patients including
long-term open-label trials out to one year. One case of aminotransferase
elevations > 3 x ULN has been accompanied by bilirubin elevations > 2 x
ULN. Because these changes are a marker for potentially serious liver injury,
serum aminotransferase levels (and bilirubin if aminotransferase levels are
elevated) must be measured prior to initiation of treatment and then monthly.
In the post-marketing period with another endothelin
receptor antagonist (ERA), bosentan, rare cases of unexplained hepatic
cirrhosis were reported after prolonged ( > 12 months) therapy. In at least
one case with bosentan, a late presentation (after > 20 months of treatment)
included pronounced elevations in aminotransferases and bilirubin levels
accompanied by non-specific symptoms, all of which resolved slowly over time
after discontinuation of the suspect drug. This case reinforces the importance
of strict adherence to the monthly monitoring schedule for the duration of
treatment.
Elevations in aminotransferases require close attention.
LETAIRIS should generally be avoided in patients with elevated
aminotransferases ( > 3 x ULN) at baseline because monitoring liver injury may
be more difficult. If liver aminotransferase elevations are accompanied by
clinical symptoms of liver injury (such as nausea, vomiting, fever, abdominal
pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin > 2
x ULN, treatment should be stopped. There is no experience with the re-introduction
of LETAIRIS in these circumstances.
CONTRAINDICATION: PREGNANCY
LETAIRIS is very likely to produce serious birth defects if used by pregnant
women, as this effect has been seen consistently when it is administered to
animals [see CONTRAINDICATIONS]. Pregnancy must
therefore be excluded before the initiation of treatment with LETAIRIS and
prevented during treatment and for one month after stopping treatment by the
use of two acceptable methods of contraception unless the patient has had
a tubal sterilization or chooses to use a Copper T 380A IUD or LNg 20 IUS,
in which case no additional contraception is needed. Obtain monthly pregnancy
tests.
Because of the risks of liver injury and birth defects, LETAIRIS is available
only through a special restricted distribution program called the LETAIRIS
Education and Access Program (LEAP), by calling 1-866-664-LEAP (5327). Only
prescribers and pharmacies registered with LEAP may prescribe and distribute
LETAIRIS. In addition, LETAIRIS may be dispensed only to patients who are
enrolled in and meet all conditions of LEAP [see WARNINGS AND PRECAUTIONS].


DRUG DESCRIPTION



What are the possible side effects of ambrisentan (Letairis)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling short of breath;
fast or pounding heartbeats;
swelling of the feet, ankles, or legs;
nausea, stomach pain, loss of appetite, low fever, itching;
dark urine, clay-colored stools; or
jaundice...
Read All Potential Side Effects for Letairis »




LETAIRIS is the brand name for ambrisentan, an endothelin
receptor antagonist that is selective for the endothelin type-A (ETA) receptor.
The chemical name of ambrisentan is
(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic
acid. It has a molecular formula of C22H22N2O4
and a molecular weight of 378.42. It contains a single chiral center determined
to be the (S) configuration and has the following structural formula:
Figure 1: Ambrisentan Structural Formula








Ambrisentan is a white to off-white, crystalline solid. It
is a carboxylic acid with a pKa of 4.0. Ambrisentan is practically insoluble in
water and in aqueous solutions at low pH. Solubility increases in aqueous
solutions at higher pH. In the solid state ambrisentan is very stable, is not
hygroscopic, and is not light sensitive.
LETAIRIS is available as 5 mg and 10 mg film-coated tablets
for once-daily oral administration. The tablets include the following inactive
ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate and
microcrystalline cellulose. The tablets are film-coated with a coating material
containing FD&C Red #40 aluminum lake, lecithin, polyethylene glycol,
polyvinyl alcohol, talc, and titanium dioxide. Each square, pale pink LETAIRIS
tablet contains 5 mg of ambrisentan. Each oval, deep pink LETAIRIS tablet
contains 10 mg of ambrisentan. LETAIRIS tablets are unscored.
Last reviewed on RxList: 7/16/2009





Other reviews about Letairis on wordpress

Letairis --worth $50,000/year?
  by medicynic
A new drug for pulmonary arterial hypertension (PAH) Letairis has been released. In PAH small arteries in the lungs narrow and the pressure of blood in the vessels […]


Blood Pressure Drug Approved
  by veronicafoster
The Food and Drug Administration said it approved Letairis to treat pulmonary arterial hypertension. The condition causes continuous high blood pressure in the arteries that carry oxygen-poor blood […]


New Orphan Drug For Pulmonary Hypertension
  by heremias
On Friday June 15th 2007, the Food and Drug Administration (FDA) approved a new drug for the treatment of pulmonary arterial hypertension. Letairis (ambrisentan) is an endothelin receptor […]


FINALLY!!!
  by mommyshands
After waiting and twiddling my thumbs for 3 weeks, I took a proactive stance and decided to find out what was happening with my new medicine, Letairis.  Called […]


Surprise!!! Twice in one week!
  by mommyshands
Boy, what a treat for you all!  You get to hear the boring details of my illnesses sooner than you thought.  Well, I made the decision to move my […]


Gilead initiate ambrisentan trial in PAH with sildenafil
  by crimsoncanary
Gilead have initiated a phase IV trial of Letairis (ambrisentan) in Pulmonary Arterial Hypertension (PAH) patients who have not demonstrated an optimal response on sildenafil therapy alone. […]


FDA Approves Unconsumed Junk Item whereas Monograph anent
  by annuncitadianawwe
FDA Approves Intact Forsaken Paralyze pro Arrangement as regards Panting Lane HULIQ.com - The U.S. Rations and arkansas ware rehab Chocolate Wardship(FDA) allowed astraddle June […]


FDA Approves Unconsumed Junk Item whereas Monograph anent
  by annuncitadianawwe
FDA Approves Intact Forsaken Paralyze pro Arrangement as regards Panting Lane HULIQ.com - The U.S. Rations and arkansas ware rehab Chocolate Wardship(FDA) allowed astraddle June […]


Links
  by pulmonaryhypertension
Pulmonary Hypertension Association www.phassociation.org Find a Doctor www.phassociation.org/Find_A_Doctor/ PHA's Advocacy Page www.phassociation.org/advocacy/ Pulmonary Hypertension on Facebook http://www.facebook.com/home.php#/group.php?gid=2215738619 Snanimals (Hand-painted shoes in memory of Emma) http://www.snanimals.com/cure-ph-products.html From the Heart Jewels (Handmade jewelry by a PH patient) www.fromtheheartjewels.etsy.com Clinical Trials http://clinicaltrials.gov/ Drug Companies and […]


FDA MedWatch - July 2009 Drug Safety Labeling Changes
  by irbtipoftheweek
The MedWatch July 2009 Drug Safety Labeling Changes posting includes 38 drug products with safety labeling changes to the following sections: BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, […]



Other reviews about Letairis on web:

Letairis ® (ambrisentan) is a prescription medicine to treat pulmonary arterial hypertension (PAH), which is high blood pressure in the arteries of your lungs. Letairis Web Site


Letairis (ambrisentan) is used to treat pulmonary arterial hypertension (PAH). Includes Letairis side effects, interactions and indications. Letairis Information from Drugs.com


Learn about the prescription medication Letairis (Ambrisentan Tablets), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Letairis (Ambrisentan Tablets) Drug Information: Uses, Side ...


Ambrisentan (U.S. trade name Letairis; E.U. trade name Volibris) is a drug indicated for use in the treatment of pulmonary hypertension. It functions as an endothelin receptor ... Ambrisentan - Wikipedia, the free encyclopedia


Click Here for a Free PAH / PPH Information Packet. FOR MORE INFORMATION Please call 1-800-923-6376. We will gladly answer your Letairis - Letairis and PAH / PPH


Accurate, FDA approved Letairis information for healthcare professionals and patients - brought to you by Drugs.com. Letairis Official FDA information, side effects and uses.


HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LETAIRIS™ tablets safely and effectively. Letairis Package Insert


What is Letairis (Ambrisentan)? Ambrisentan prevents thickening of the blood vessels, especially those in the lungs and heart. Ambrisentan also lowers blood pressure in your lungs ... Letairis - Drugs & Treatments - Revolution Health


Users share their experience with Letairis and comment on drug side effects, effectiveness, and treatment knowledge Letairis Drug and Medication User Reviews on RxList


Find patient medical information for Letairis Oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Letairis Oral : Uses, Side Effects, Interactions, Pictures ...





Featured Reviews

Reviews Luvox CR

Luvox CR Drug Description LUVOX® CR (fluvoxamine maleate) Extended-Release Capsules 100 mg and 150 mg Suicidally and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior...
Read More  |  Review This
Reviews Dilacor XR

Dilacor XR Drug Description Dilacor XR (diltiazem HCl) Extended-release Capsules DRUG DESCRIPTION What are the possible side effects of diltiazem? Get emergency medical help if you have any of these signs of an allergic reaction:...
Read More  |  Review This
Reviews Budesonide and Formoterol Fumarate Dihydrate

Symbicort Drug Description SYMBICORT® 80/4.5 (budesonide 80 mcg and formoterol fumarate dihydrate* 4.5 mcg) Inhalation Aerosol SYMBICORT® 160/4.5 (budesonide 160 mcg and formoterol fumarate dihydrate* 4.5 mcg) Inhalation Aerosol WARNING...
Read More  |  Review This
Reviews Cortrosyn

Cortrosyn Drug Description CORTROSYN™ (cosyntropin) for Injection DRUG DESCRIPTION CORTROSYN™ (cosyntropin) for Injection is a sterile Iyophilized powder in vials containing 0.25 mg of CORTROSYN™ and 10 mg of mannitol...
Read More  |  Review This
Reviews Cytarabine Liposome Injection

DepoCyt Drug Description DEPOCYT® (cytarabine liposome injection) For Intrathecal Use Only 50 mg vial WARNING DepoCyt® (cytarabine liposome injection) should be administered only under the supervision of a qualified...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....